Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

ASAHI KASEI Aktie

 >ASAHI KASEI Aktienkurs 
8.398 EUR    -3.7%    (TradegateBSX)
Ask: 8.56 EUR / 578 Stück
Bid: 8.306 EUR / 595 Stück
Tagesumsatz: 600 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ASAHI KASEI Aktie über LYNX handeln
>ASAHI KASEI Performance
1 Woche: -1,1%
1 Monat: -12,0%
3 Monate: +12,0%
6 Monate: +24,8%
1 Jahr: +33,2%
laufendes Jahr: +12,1%
>ASAHI KASEI Aktie
Name:  ASAHI KASEI
Land:  Japan
Sektor:  Mischkonzerne
ISIN/ Wkn:  JP3111200006 / 857993
Symbol/ Ticker:  ASAA (Frankfurt)
Kürzel:  FRA:ASAA, ETR:ASAA, ASAA:GR
Index:  Nikkei225
Webseite:  https://www.asahi-kasei.c..
Profil:  Asahi Kasei Corporation is a diversified Japanese conglomerate specializing in chemicals, materials, residential construction, and healthcare solutions. Originally founded in 1931 and headquartered in Tokyo, Asahi Kasei operates through four primary ..
>Volltext..
Marktkapitalisierung:  11735.66 Mio. EUR
Unternehmenswert:  15954.11 Mio. EUR
Umsatz:  16801.24 Mio. EUR
EBITDA:  2310.73 Mio. EUR
Nettogewinn:  868.6 Mio. EUR
Gewinn je Aktie:  0.64 EUR
Schulden:  6304.68 Mio. EUR
Liquide Mittel:  2437.23 Mio. EUR
Operativer Cashflow:  1696.74 Mio. EUR
Bargeldquote:  0.48
Umsatzwachstum:  -9.81%
Gewinnwachstum:  65.98%
Dividende je Aktie:  0.11 EUR
Dividendenrendite:  2.55%
Dividendenschätzung:  2.59%
Div. Historie:  29.09.25 - 0.113952€
28.03.25 - 0.113952€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  ASAHI KASEI
Letzte Datenerhebung:  05.04.26
>ASAHI KASEI Kennzahlen
Aktien/ Unternehmen:
Aktien: 1356.44 Mio. St.
Frei handelbar: 84.28%
Leerverk. Aktien: -
Rückkaufquote: 0.24%
Mitarbeiter: 50352
Umsatz/Mitarb.: 0.35 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 23.01%
Bewertung:
KGV: 13.11
KGV lG: 14.25
KUV: 0.68
KBV: 1.03
PEG-Ratio: 0.14
EV/EBITDA: 6.9
Rentabilität:
Bruttomarge: 32.49%
Gewinnmarge: 5.17%
Operative Marge: 7.29%
Managementeffizenz:
Gesamtkaprendite: 3.82%
Eigenkaprendite: 8.08%
>ASAHI KASEI Peer Group
Mischkonzerne, Automobilzulieferer, Medizinprodukte & -technik/ Implantate/ Wundpflege, Spezialchemie
 
02.04.26 - 09:06
Asahi Kasei enters AI chip fiberglass market to challenge Nittobo′s dominance (Digitimes)
 
Japan's Asahi Kasei has announced its official entry into the AI chip supply chain with fiberglass cloth as an insulating substrate material, targeting the current global leader Nittobo, which holds a 90% market share. Meanwhile, Nippon Electric Glass (NEG) also plans to invest in AI-specific fiberglass cloth, signaling accelerated competition among Japanese materials makers for semiconductor opportunities....
01.04.26 - 19:00
Japan glassmakers Asahi Kasei, AGC retool to ride surging AI chip demand (Nikkei)
 
Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...
23.03.26 - 15:06
Sudden Cardiac Death Risk and Heart Failure Management at ACC.26 – How ZOLL Innovations Redefine Protection (Business Wire)
 
CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, will highlight the latest sudden cardiac death research, case experiences for heart failure readmission reduction, and two Innovation Stage presentations at the American College of Cardiology Annual Scientific Session & Expo (ACC.26), March 28-30, 2026. ZOLL will sponsor a slate of educational programs to engage and connect clinicians with emerging evidence and evolving practices in cardiac care: The ACC Innovation Stage will host two ZOLL-sponsored presentations: A friendly debate about approaches to HFrEF patient management with GDMT, including the LifeVest® wearable cardioverter defibrillator (WCD) as a treatment option. A case study highlighting a reduction in HF readmission to single digits with the implementation of ZOLL's Heart Failure Management System (HFMS). ZOLL is sponsoring the ACC Women in Cardiology Mix N' Mingle, as well as events for cardiology fellows an...
19.03.26 - 16:18
Chevron Technology Ventures, Asahi Kasei Invest in Heavy-Industry Robotics Company KEWAZO (Business Wire)
 
KEWAZO's LIFTBOT Is Automating Maintenance and Capital Projects Across the Energy SectorMUNICH & HOUSTON--(BUSINESS WIRE)--KEWAZO, the robotics company transforming heavy industry worldwide, today announced a new funding round backed by Chevron Technology Ventures, Asahi Kasei, Benson Capital, Mana Ventures, Gaingels, and Atlas Ventures, alongside lead investor Schooner Capital and existing investors True Ventures and Cybernetix Ventures. Total funding now reaches $35M. KEWAZO's lifting robot LIFTBOT is already deployed at more than 20 industrial sites in North America and Europe, including refineries, petrochemical plants, chemical complexes, and power facilities. Asset owners and service providers are increasingly adopting LIFTBOT to replace cranes and manual handling - improving safety and efficiency while bringing greater schedule predictability to maintenance, turnarounds, and capital projects. Enabling the Physical AI Future of Industrial Sites LIFTBOT deployments grant KEWAZO access to high-barri...
17.03.26 - 16:31
Here′s Why Asahi Kasei (AHKSY) Could be Great Choice for a Bottom Fisher (Zacks)
 
Asahi Kasei (AHKSY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term....
12.03.26 - 14:18
Japanese Chemical Makers Cutting Ethylene Output (Nippon)
 
Tokyo, March 12 (Jiji Press)--Major Japanese chemical manufacturers have begun reducing ethylene production amid the deteriorating situation in the Middle East. On Thursday, Mitsubishi Chemical Corp. and Asahi Kasei Corp. announced that they have lowered the operational rate at their joint facility in Kurashiki, Okayama Prefecture, western Japan. This is the fourth ethylene production fa......
27.02.26 - 12:48
Asahi Kasei to acquire Aicuris Anti-infective Cures for $920.7m (PBR)
 
The acquisition will expand the company's speciality pharmaceutical platform into severe infectious diseases. Completion is expected in the first quarter of fiscal 2026, subject to customary conditions. The The post Asahi Kasei to acquire Aicuris Anti-infective Cures for $920.7m appeared first on Pharmaceutical Business review....
27.02.26 - 02:24
Asahi Kasei to Acquire German Drug Developer Aicuris (Nippon)
 
Tokyo, Feb. 27 (Jiji Press)--Asahi Kasei Corp. has said it will acquire German pharmaceutical developer Aicuris Anti-Infective Cures AG for some 780 million euros. The major Japanese chemical maker will obtain all outstanding Aicuris shares through a U.S. subsidiary, planning to complete the acquisition in April-June. Asahi Kasei aims to expand profits in the medical field, a growth area for......
26.02.26 - 14:16
Biotech-Deal: Japanischer Konzern übernimmt Wuppertaler Viren-Spezialisten (Business Insider DE)
 
Das Wuppertaler Biotech-Unternehmen Aicuris wird für rund 920 Millionen Dollar vom japanischen Konzern Asahi Kasei übernommen....
26.02.26 - 13:33
Asahi Kasei Strengthens Global Pharmaceutical Platform with the Acquisition of Aicuris (Business Wire)
 
Advancing Expansion in Severe Infectious Disease and Leveraging Existing Global Infrastructure to Drive Long-Term GrowthCHELMSFORD, Mass. & TOKYO--(BUSINESS WIRE)--Asahi Kasei announced it has entered into a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures AG, a German-based biopharmaceutical company, for approximately €780 million*. This transaction expands Asahi Kasei's specialty pharmaceutical platform further into severe infectious diseases and is expected to close in the first quarter of fiscal 2026, subject to customary conditions. Asahi Kasei expects the acquisition to contribute positively to operating income after amortization of goodwill and other intangible assets from fiscal 2028 onward. The acquisition advances Asahi Kasei's strategy to build a focused, sustainable specialty pharmaceutical platform serving immunocompromised and medically complex patient populations. Severe infectious diseases represent an area where Asahi Kasei already maintains a presence...
26.02.26 - 10:55
Asahi Kasei kauft Wuppertaler Biotechfirma Aicuris für 780 Millionen Euro (Reuters)
 
Um den gesamten Artikel unter onvista.de zu lesen, klicken Sie bitte auf die Überschrift...
26.02.26 - 10:18
Asahi Kasei stärkt globales Pharmageschäft mit Übernahme von deutschem Unternehmen Aicuris (News Aktuell)
 
Asahi Kasei: CHELMSFORD, Mass. & TOKIO (ots) - Asahi Kasei wird alle Anteile des deutschen Biopharmaunternehmens Aicuris Anti-infective Cures AG für etwa 780 Millionen Euro erwerben. Mit dieser Transaktion, die voraussichtlich im ersten Quartal des ......
26.02.26 - 08:12
Asahi Kasei übernimmt Aicuris für 780 Mio. EUR (GoingPublic)
 
Bildnachweis: ©crevis – stock.adobe.com. 780 Mio. Euro für ein deutsches Antiinfektiva-Biotech: Asahi Kasei übernimmt die in Wuppertal ansässige Aicuris vollständig – abgewickelt über die US-Tochter Veloxis Pharmaceuticals. Mit dem etablierten […] Der Beitrag Asahi Kasei übernimmt Aicuris für 780 Mio. EUR erschien zuerst auf GoingPublic.de....
26.02.26 - 08:09
Übernahme! Deutsche Biotech-Firma wird aufgekauft (Der Aktionaer)
 
Das Übernahme-Karussell im Biotech-Sektor bleibt mächtig in Bewegung. Veloxis Pharmaceuticals, eine US-amerikanische Tochtergesellschaft des japanischen Technologie-Konzerns Asahi Kasei, will die deutsche Biotechnologie-Gesellschaft AiCuris schlucken und legt dafür satte 920 Millionen Dollar auf den Tisch....
19.02.26 - 20:03
MAIA Pharmaceuticals Selected by Asahi Kasei Pharma to Advance Teribone™ for US Osteoporosis Patients (PR Newswire)
 
A proven bone-forming osteoporosis therapy optimized for real-world use and patient compliance PRINCETON, N.J., Feb. 19, 2026 /PRNewswire/ -- MAIA Pharmaceuticals, Inc. today announced a strategic collaboration with Asahi Kasei Pharma Corp., under which MAIA will advance Teribone™......
04.02.26 - 15:33
ZOLL Medical Appoints Eric Knudsen as New CEO (Business Wire)
 
CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has appointed Eric Knudsen as its new Chief Executive Officer, effective April 1. Knudsen will succeed Jon Rennert, who served as ZOLL's CEO for the past 10 years and will assume a new role as Executive Chairman of ZOLL's Board of Directors. “As a global leader in medical technology, ZOLL is continually looking for ways to expand our business and reach more patients in need,” said Rennert. “Eric has played a unique role in developing our growth strategies and driving our expansion, and I am confident he will lead ZOLL to even greater growth and success.” “I am honored to become ZOLL's next CEO,” said Knudsen. “ZOLL has a long legacy of innovation and clinical excellence, and today our medical devices, software, and related services are used worldwide to diagnose and treat patients suffering from serious cardiopulmonary and respiratory...
04.02.26 - 06:30
Asahi Kasei 9-month Profit Climbs, Lifts FY25 Profit View, Cuts Sales Forecast; Stock Gains (AFX)
 
TOKYO (dpa-AFX) - Asahi Kasei Corp. (3407.T, AHKSF), a material, homes and healthcare business firm, reported Wednesday higher profit in the first nine-months of fiscal 2025, amid slightly higher ......
04.02.26 - 06:24
Asahi Kasei Corporation Nine Months Income Climbs (AFX)
 
TOKYO (dpa-AFX) - Asahi Kasei Corporation (AHKSF) released a profit for its nine months that Increased, from the same period last yearThe company's bottom line came in at JPY120.607 billion, or JP......
28.01.26 - 07:18
3 Firms to Consolidate Ethylene Production in Western Japan (Nippon)
 
Tokyo, Jan. 28 (Jiji Press)--Mitsubishi Chemical Corp., Asahi Kasei Corp. and Mitsui Chemicals Inc. have said they will consolidate their ethylene production facilities in western Japan as early as fiscal 2030. Specifically, the ethylene production facility in Kurashiki in the western prefecture of Okayama, which is operated by Mitsubishi Chemical and Asahi Kasei, will end operations. Mit......
27.01.26 - 07:30
Asahi Kasei, Mitsui, Mitsubishi Join To Promote Decarbonization Of Ethylene Production (AFX)
 
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Asahi Kasei (3407.T), Mitsui Chemicals (4183.T), and Mitsubishi Chemical (4188.T) have entered basic agreement to promote decarbonization and optimize producti......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!